Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs)... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
COYA is expected to report earnings to rise 118.75% to -69 cents per share on August 18
Q2'26
Est.
$-0.70
Q1'26
Beat
by $0.37
Q4'25
Beat
by $0.31
Q3'25
Beat
by $0.46
Q2'25
Missed
by $0.49
The last earnings report on May 11 showed earnings per share of -31 cents, beating the estimate of -68 cents. With 249.39K shares outstanding, the current market capitalization sits at 142.39M.